Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Blood (2017) 129 (7): 846–854.

https://doi.org/10.1182/blood-2016-09-742205

Published: 2017

Journal Articles

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Delphine Rea, MD PhD, Franck E. Nicolini, MD PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Francois Guilhot, MD, Martine Gardembas, MD, Agnès Guerci, MD, Valérie Coiteux, MD, Laurence Legros, MD PhD, Gaelle Guillerm, MD, Jean Michel Pignon, MD, Stephane Giraudier, MD PhD, Gabriel Etienne, Bruno Villemagne, MD, Martine Escoffre, MD, Aude Charbonnier, MD PhD, Francois-Xavier Mahon, MD PhD

Blood (2014) 124 (21): 811.

https://doi.org/10.1182/blood.V124.21.811.811

Published: 2014

Journal Articles

Quality Of Life In CML Patients: Better Outcomes Associated With TKI Interruption

Stephane Giraudier, MD, PhD, Etienne Audureau, MD, PhD, Kahina Oukerfellah, MSc, Michel Tulliez, MD

Blood (2013) 122 (21): 4004.

https://doi.org/10.1182/blood.V122.21.4004.4004

Published: 2013

Journal Articles

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Blood (2013) 122 (21): 4030.

https://doi.org/10.1182/blood.V122.21.4030.4030

Published: 2013

Journal Articles

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Blood (2013) 122 (21): 381.

https://doi.org/10.1182/blood.V122.21.381.381

Published: 2013

Journal Articles

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Clémence Roux, Franck-Emmanuel Nicolini, Delphine Rea, Mathilde Niault, Luigina Mollica, Françoise Berger, Catherine Chassagne-Clément, Isabelle Tigaud, Michel Tulliez, Stéphane Giraudier, Ali Turhan, Philippe Rousselot, Laurence Legros

Blood (2013) 122 (17): 3082–3084.

https://doi.org/10.1182/blood-2013-07-513879

Published: 2013

Journal Articles

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Delphine Rea, MD, PhD, Philippe Rousselot, MD, PhD, François Guilhot, MD, Michel Tulliez, MD, Franck E. Nicolini, MD, PhD, Agnès Guerci-Bresler, MD, Laurence Legros, MD, PhD, Martine Gardembas, MD, Stephane Giraudier, MD, PhD, Gaelle Guillerm, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 916.

https://doi.org/10.1182/blood.V120.21.916.916

Published: 2012

Journal Articles

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

Laurence Legros, Philippe Rousselot, Stéphane Giraudier, Michel Tulliez, Françoise Huguet, Franck-Emmanuel Nicolini, Francois-Xavier Mahon

Blood (2012) 120 (9): 1959–1960.

https://doi.org/10.1182/blood-2012-02-408229

Published: 2012

Journal Articles

Fluctuating Values of Molecular Residual Disease (MRD) without Molecular Progression After Imatinib Discontinuation in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Have Maintained Complete Molecular Response: Implications for Re-Treatment Criteria and Role of Prior Interferon Therapy. A Pilot Study of the French CML Group (FILMC),

Philippe Rousselot, MD, PhD, Pascale Cony Makhoul, Delphine Rea, MD, Philippe Agape, Franck E Nicolini, MD, Laurence Legros, Michel Tulliez, Lydia Roy, Aude Charbonnier, Joelle Guilhot, Francois Guilhot, Francois-Xavier Mahon, MD, PhD

Blood (2011) 118 (21): 3781.

https://doi.org/10.1182/blood.V118.21.3781.3781

Published: 2011

Journal Articles

EOSTA: An Observational Study on the Compliance and Quality of Life (QoL) of Chronic Myeloid Leukemia (CML) Patients Treated with Second Line Nilotinib (Tasigna®) : Interim Results At 6 Months of Follow-up,

Delphine Rea, MD, PhD, Frédéric Maloisel, MD, Françoise Huguet, MD, Hikaru Okada, MD, PhD, Isabelle Bourdeix, Franck E. Nicolini, MD, PhD, Michel Tulliez, Gabriel Etienne, MD, PhD

Blood (2011) 118 (21): 3782.

https://doi.org/10.1182/blood.V118.21.3782.3782

Published: 2011

Journal Articles

Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC)

Delphine Rea, MD, Philippe Rousselot, MD, PhD, Franck E. Nicolini, MD, PhD, Laurence Legros, Michel Tulliez, Stephane Giraudier, MD, PhD, Pascale Cony-Makhoul, MD, François Guilhot, MD, PhD, Francois-Xavier Mahon, MD, PhD

Blood (2011) 118 (21): 604.

https://doi.org/10.1182/blood.V118.21.604.604

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD

Blood (2010) 116 (21): 3378.

https://doi.org/10.1182/blood.V116.21.3378.3378

Published: 2010

Journal Articles

Cartridge-Based Automated BCR-ABL mRNA Quantification: Towards Simplified Standardisation.

Jean-Michel Cayuela, PhD, PharmD, Elizabeth Macintyre, MD, PhD, Meryl Darlington, Raouf Ben Abdelali, MD, Xavier Fund, Patrick Villarèse, William Piterboth, Michel Tulliez, MD, Emmanuel Raffoux, MD, Francois Sigaux, MD, PhD, Delphine Rea, MD, PhD, Dominique Bories, MD, PhD, Valerie Seror

Blood (2009) 114 (22): 4261.

https://doi.org/10.1182/blood.V114.22.4261.4261

Published: 2009

Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (2009) 114 (22): 3293.

https://doi.org/10.1182/blood.V114.22.3293.3293

Published: 2009

Journal Articles

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Delphine Rea, MD, PhD, Gabriel Etienne, MD, Franck Emmanuel Nicolini, MD, PhD, Pascale Cony-Makhoul, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD, Francoise Huguet, MD, Michel Tulliez, MD, Martine Gardembas, MD, Krimo Bouabdallah, MD, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, PhD, Herve Dombret, MD, PhD, François-Xavier Mahon, MD, PhD

Blood (2009) 114 (22): 3288.

https://doi.org/10.1182/blood.V114.22.3288.3288

Published: 2009

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Detection of JAK2 V617F in the Diagnosis of Erythrocytosis: Feasibility and Diagnostic Value in Clinical Practice.

Chloé James, François Delhommeau, Christophe Marzac, Irène Teyssandier, Jean-Pierre Le Couédic, Stéphane Giraudier, Lydia Roy, Patrick Saulnier, Michel Tulliez, William Vainchenker, Nicole Casadevall, Valérie Ugo

Blood (2005) 106 (11): 2595.

https://doi.org/10.1182/blood.V106.11.2595.2595

Published: 2005

NARROW

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc

Quality Of Life In CML Patients: Better Outcomes Associated With TKI Interruption

Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

EOSTA: An Observational Study on the Compliance and Quality of Life (QoL) of Chronic Myeloid Leukemia (CML) Patients Treated with Second Line Nilotinib (Tasigna®) : Interim Results At 6 Months of Follow-up,

Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC)

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Cartridge-Based Automated BCR-ABL mRNA Quantification: Towards Simplified Standardisation.

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Detection of JAK2 V617F in the Diagnosis of Erythrocytosis: Feasibility and Diagnostic Value in Clinical Practice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only